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γ-glutamyl carboxylase (GGCX)VKORC1 and VKORC1L1 are enzymes that both catalyze the reduction of vitamin K2,3-epoxide via vitamin K
quinone to vitamin K hydroquinone. VKORC1 is the key enzyme of the classical vitamin K cycle bywhich vitamin
K-dependent (VKD) proteins are γ-carboxylated by the hepatic γ-glutamyl carboxylase (GGCX). In contrast, the
VKORC1 paralog enzyme, VKORC1L1, is chieﬂy responsible for antioxidative function by reduction of vitamin K to
prevent damage by intracellular reactive oxygen species. To investigate tissue-speciﬁc vitamin K 2,3-epoxide re-
ductase (VKOR) function of both enzymes, we quantiﬁed mRNA levels for VKORC1, VKORC1L1, GGCX, and NQO1
andmeasuredVKOR enzymatic activities in 29differentmouse tissues.VKORC1 andGGCX are highly expressed in
liver, lung and exocrine tissues including mammary gland, salivary gland and prostate suggesting important ex-
trahepatic roles for the vitamin K cycle. Interestingly, VKORC1L1 showed highest transcription levels in brain.
Due to the absence of detectable NQO1 transcription in liver, we assume this enzyme has no bypass function
with respect to activation of VKD coagulation proteins. Our data strongly suggest diverse functions for the vita-
min K cycle in extrahepatic biological pathways.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) is the
key enzyme of the vitamin K cycle essential for post-translational mod-
iﬁcation of vitamin K-dependent proteins (VKD proteins) [1,2]. VKD
proteins are modiﬁed by the γ-glutamyl carboxylase (GGCX) which
converts speciﬁc glutamic acid residues to γ-glutamyl dicarboxylic
acid (Gla) residues. This modiﬁcation confers VKD proteins with their
biological activities. Simultaneously, GGCX oxidizes vitamin K hydro-
quinone to vitamin K 2,3-epoxide. In turn, VKORC1 subsequently re-
duces vitamin K 2,3-epoxide back to the quinone and hydroquinonest-speciﬁc protein 6; GGCX, γ-
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(M. Watzka),
. This is an open access article underforms, completing a vitamin K redox cycle known as the "vitamin K
cycle" [3].
The paralog enzyme of VKORC1, VKORC1-like 1 (VKORC1L1), also
functions both as a vitamin K 2,3-epoxide reductase and as a vitamin
K quinone reductase, but has lower afﬁnity for K vitamins compared
to that of VKORC1 [4]. Additionally, VKORC1L1 appears not to be capable
of driving the classical vitamin K cycle to adequately produce activated
VKD clotting factor proteins in VKORC1 knock-out mice [5,6]. However,
during experimentally-induced oxidative stress, VKORC1L1 mRNA is
signiﬁcantly upregulated in vitro, suggesting its function in antioxida-
tive pathways as protective against free radicals [4].
Since the 1980s, it has been speculated that NAD(P)H:quinone oxi-
doreductase 1 (NQO1) might function as a bypass enzyme in the vita-
min K cycle in cases of 4-hydroxycoumarin intoxication where large
doses of vitamin K have been known to be antidotal [7]. Compared to
VKORC1, NQO1 is several orders of magnitude less sensitive to 4-
hydroxycoumarin inhibition and catalyzes the reduction of vitamin K
quinone only at high, non-physiological vitamin K concentrations
in vitro [8–10]. However, recent studies concluded that NQO1 is not re-
sponsible for γ-carboxylation of VKD proteins in the classical vitamin K
cycle in in vitro cell studies as well as in NQO1-deﬁcient mice [11,12,7].
Apart from the well-established functions of VKORC1 and GGCX in
the vitamin K cycle, including enabling haemostatic pathways by γ-
carboxylation of VKD coagulation factors (e.g. FII, FVII, FIX, FX), theirthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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VKD proteins with a wide diversity of non-haemostatic functions have
been reported. For example, matrix Gla-protein (MGP) and osteocalcin
are involved in calcium regulation and bone homeostasis. MGP was
found to act as a calciﬁcation inhibitor in vivo [13]. Signiﬁcantly higher
rates of vascular calciﬁcation and associated aortic rupture were ob-
served inMGP-knockoutmice [13]. Osteocalcin is a physiological mark-
er for osteoblast activity and bone formation and plays an important
role in regulating bonemetabolism [14–16]. Recent animal studies sug-
gest an additional connection between bone remodeling and systemic
metabolism as osteocalcin-deﬁcient mice are hyperglycemic and
hypoinsulinemic [17]. Another VKD protein, growth arrest-speciﬁc pro-
tein 6 (Gas 6), is implicated in the regulation of multiple cellular func-
tions including growth, anti-apoptotic pathways, cell adhesion, and
chemotaxis [18–21]. The VKD protein periostin was found to play a
role in prenatal heart development [22]. Additionally, biological func-
tions are not known for additionally discovered VKD proteins including
PRGP1 through PRGP4 [23–27].
The present study aims to provide more insight into the role of the
vitamin K cycle in extrahepatic tissues by examining mRNA levels of
the vitamin K cycle-related enzymes VKORC1, VKORC1L1, GGCX and
NQO1 and the vitamin K 2,3-epoxide reductase (VKOR) activity in 29
distinct mouse tissues.
Materials and Methods
Mouse Tissue Preparation
Microsomes and mRNA were prepared from various tissues of
7 week-old male and female CD1 wild-type mice (ﬁve of each sex;
Charles River Laboratories International, Sulzfeld, Germany). Mice
were sacriﬁced and 29 different tissueswere dissected including (1) ad-
renal gland, (2) bone, (3) brain, (4) caecum, (5) colon, (6) diaphragm,
(7) duodenum, (8) eye, (9) heart, (10) kidney, (11) liver, (12) lung,
(13) lymph node, (14) mammary gland, (15) masseter muscle,
(16) muscle, (17) oesophagus, (18) pancreas, (19) salivary gland,
(20) skin, (21) soft tissue, (22) stomach, (23) spleen, (24) tongue,
(25) vessels, (26f) ovary, and (27f) uterus from females, and (26m) tes-
tis and (27 m) prostate from males. The excised tissues were snap-
frozen in liquid nitrogen and stored at -80 °C until use.
Preparation of mRNA and Real Time PCR
Isolation of mRNA from excised tissues was performed using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s recommendations. Reverse transcription of mRNA was per-
formed using the QuantiTect Reverse Transcription-Kit (Qiagen) in
conjunction with oligo-dT primers and hexanucleotides. Real-time
PCR was performed using 2 μl of cDNA and the ABsolute QPCR Mix
including ROX (Thermo Fisher, Hamburg, Germany). For the prepara-
tion of standards, cDNAs of VKORC1, VKORC1L1, GGCX, NQO1 and
hydroxymethylbilanesynthase (HMBS, a housekeeping-gene) were
cloned into pGEM-T vectors using the pGEM-T Easy vector system kit
(Promega, Madison, USA). Since exocrine pancreas produces high con-
centrations of RNase, this tissue was excluded from mRNA quantiﬁca-
tion experiments. For direct comparison of VKORC1 and VKORC1L1
transcription, both sequences were cloned in tandem into pGEM-T
vectors and used as standards for examination of liver and brain tissues.
Standard curves for real-time PCR experiments were prepared by serial
dilutions of the vectors to yield one to 107 copies. VKORC1, VKORC1L1,
GGCX andNQO1 transcription levelswere calculated according to the re-
spective standard curves and normalized to determined constitutive
HMBS transcription levels. Probes were labeled with FAM at the 5´-
prime end and with a black-hole-quencher (BHQ) at the 3´-prime end.
Real-time PCR was performed using the ABI Prism 7700 Sequencedetection system. All assays were performed in duplicate. Primer se-
quences are listed in the online supplementary ﬁle.
Preparation of Microsomes
Frozen tissue samplesweremechanically disrupted and homogenised
in 500 μL ice cold buffer A (250 mM sucrose, 25 mM imidazol, 80 mM
KCl, pH 7.6) [28]. To reduce protease activity, a protease inhibitor (Com-
plete Mini, Roche Applied Science, Mannheim, Germany) was added to
buffer A. The following tissues were pooled (male and female samples
separately) due to the small amounts of sample material: adrenal
gland, bone, ceacum, colon, diaphragm, eye, mammary gland, oesopha-
gus, salivary gland, skin, aorta, vessels, tongue, masseter muscle, lymph
node, ovary, uterus, duodenum, testis, prostate. All other tissues were
analyzed for each mouse as individual samples. Sample homogenates
were centrifuged at 10,000 xg for 10 min to remove mitochondria and
cellular debris. Microsomes were isolated from supernatants by ultra-
centrifugation at 100,000 xg for 1 h. Afterwashing themicrosomepellet
in buffer B (25 mM imidazol, 0.5% CHAPS, pH 7.6) and centrifugation at
100,000 xg for 1 h, the microsomal pellets were resuspended in 150 μL
buffer B and stored at -80 °C until further use. Storage was not longer
than 3 days prior to performing activity measurements.
DTT-driven Vitamin K 2,3-epoxide Reductase (VKOR) Activity Assay
VKOR enzymatic activity was measured using the standard dithio-
threitol (DTT)-driven method according to published procedures [1,
29]. Mircrosomes (30 μL) were mixed together with 459 μL buffer B
and 20 μL 125 mM DTT (5 mM ﬁnal concentration in the assay) on ice.
After incubation for 1 min at room temperature, 5 μL of 400 mM CaCl2
and 16 μL of 1.656mM vitamin K1 2,3-epoxide in EtOHwere added. Re-
action was stopped after incubation for 1 h at 30 °C by addition of 1 mL
isopropanol:hexane (3:2 v/v). Vitamin K2 2,3-epoxide was used in the
organic solvent mixture as internal standard (10 μl of 50 μM). After or-
ganic phase extraction, a ﬁxed volume of solvent phase was removed
(300 μl), vacuum-dried and resuspended in isopropanol:methanol
(1:4 v/v), and resolved by HPLC chromatography. Quantitation of K
vitamers was done by integration of absorbance peaks (248 nm) and
compared to 150 μM vitamin K2 standard peaks to calculate recovery
efﬁciencies.
VKOR activity was calculated as the ratio of vitamin K1 2,3-epoxide
converted to vitamin K1 quinone per time, normalized to total protein
concentration for each sample measured by the Lowry protein assay
[30]. Vitamin K epoxidation was performed by oxidation of vitamin K
quinone (Sigma-Aldrich) using H2O2 according to Tishler et al. [31].
Results
Determination of VKORC1, VKORC1L1, GGCX andNQO1 Transcription Levels
Transcription levels of VKORC1, VKORC1L1, GGCX and NQO1were in-
vestigated by real-time PCR of mRNA preparations from 29 different
CD1 wild-type mouse tissues. Presence of VKORC1 mRNA transcripts
could bedetected in all tissues examined (Fig. 1A). Highest transcription
of VKORC1mRNA (mean value 4.79 AU (arbitrary units)) was observed
for liver. In glandular tissues, high transcription levels of VKORC1were
found in salivary gland (2.84 AU) and mammary gland (2.10 AU). In
contrast, transcription in adrenal gland was much lower (1.00 AU). All
other tissues examined (with exceptions of prostate 2.71 AU and lung
2.51 AU) exhibited transcription values lower than 2.00 AU (Fig. 1A).
With the exception of skin, we found GGCX transcribed in all tissues
examined with the highest level in liver (0.45 AU), followed by lung
(0.28 AU; Fig. 1B). Preparations from testis showed low GGCX transcrip-
tion levels close to the detection limit. For all other tissues, we found in-
termediate transcription levels ranging from 0.05 to 0.2 AU.
Fig. 1.mRNA expression of VKORC1, GGCX, VKORC1L1 and NQO1 in 26 different mouse tissues. mRNA expression was evalutated of tissues of each 5 male and 5 female mice by two-step real-time PCR in duplicate. As standard the respective cDNA
cloned in pGEM-T vector was used in serial dilutions of one to 107 copies. Hydroxymethylbilanesynthase (HMBS) was used as housekeeping-gene. Mean expression levels are represented by arbitrary units (AU). Each tissue investigated is labeled at
the bottom. Error bars show the range of highest and lowest measurements representing interindividual differences in mice. Panel A show mRNA expression levels for VKORC1, Panel B transcription levels for GGCX, Panel C transcription levels for
VKORC1L1, Panel D transcription levels for NQO1.
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ined. The highest transcription level of VKORC1L1was detected in brain
(0.8 AU; Fig. 1C). In all other tissues, we found transcription levels of
VKORC1L1 ranging from 0.1 to 0.4 AU with lowest the lowest level in
liver.
NQO1 showed highest transcription in gastrointestinal tissues
(e.g., stomach 2.15 AU, caecum 1.65 AU). Lowest mRNA levels
(≤0.1 AU) were detected in liver, glandular tissue, ovar and prostate
(Fig. 1D).
Absolute quantitative comparison regarding VKORC1 and VKORC1L1
transcription using a VKORC1/VKORC1L1 bicistronic standard probe vec-
tor for liver and brain samples revealed that VKORC1 transcription in
liver was as high as VKORC1L1 transcription in brain (Fig. 2), suggesting
VKORC1L1 has a more signiﬁcant function in brain, while VKORC1 has
the dominant function in liver. The transcription level of VKORC1L1 in
liver represents 2% relative to that of VKORC1, whereas VKORC1 tran-
scription level is 50% relative to that of VKORC1L1 in brain (Fig. 2).
VKOR Activity Measurements in Microsomes
In the present study, we measured VKOR activity in microsomal
preparations from 29 different mouse tissues. Presence of VKOR activity
was detected in all tissues examined (Fig. 3). Even though most tissues
showed basal level activities, high values were found for liver, pancreas,
ovary, uterus, mammary gland, vascular tissue and salivary gland
(N1 ng K1/mg total protein/h). As expected, high activity was found
for liver (1.92 ng K1/mg total protein/h). Interestingly, pancreas showed
a comparable value (1.94 ng K1/mg total protein/h). Furthermore,
kidney, spleen, heart and lung showed activity values ranging from
0.40 to 0.89 ng K1/mg total protein/h. Activity measurements in brain
revealed comparably low values with mean activity of ≤0.57 ng K1/mg
total protein/h.
In glandular tissue, we found a gender-speciﬁc high VKOR activity
for female tissues, relative to that for male tissues, including
1.97 ng K1/mg total protein/h for mammary gland and 1.82 ng K1/mg
total protein/h for salivary gland (Fig. 4A). In comparison, activity levels
in male tissues reached only 0.58 ng K1/mg total protein/h for mamma-
ry gland and only 0.29 ng K1/mg total protein/h for salivary gland. Con-
trastingly, adrenal gland showed a mean activity of 0.72 ng K1/mg total
protein/h without signiﬁcant gender-speciﬁc difference.
In gastrointestinal tissue, higher activities were found for oesopha-
gus, stomach and colon. Only basal activity was found for duodenumFig. 2.Quantitative comparison ofmRNA transcription levels for VKORC1 and VKORC1L1 in
liver and brain. To directly comparemRNA transcription levels of VKORC1 and VKORC1L1 a
standard was used in which both cDNA sequences were cloned into pGEM-T vector. The
extent of mRNA expression for VKORC1 (white bars) and VKORC1L1 (grey bars) is
shown for liver and brain as arbitrary units (AU). Error bars represents the highest and
lowest measurement.and caecum. Very high VKOR activities for uterus (1.43 ng K1/mg total
protein/h) and ovary (1.68 ng K1/mg total protein/h) were found. In
comparison, male sex organs showed lower mean activities ranging
from 0.39 ng K1/mg total protein/h in prostate to 0.59 ng K1/mg total
protein/h in testis (Fig. 4B).
Furthermore, we investigated four muscle samples from different
origins. Samples from quadriceps femoris, diaphragm and tongue re-
vealed equalmean activity levels of 0.61 ng K1/mg total protein/h. Sam-
ples from masseter exhibited slightly lower activities than for other
muscles (Fig. 3).
Because of relatively low availability of tissue quantities, vena cava
and aorta were separately pooled with respect to gender. With a total
of 0.67 ng K1/mg total protein/h, we found signiﬁcantly lower activities
for male mice compared to 1.46 ng K1/mg total protein/h for females. In
further pooled tissues from bone, eye, skin, and soft tissue, basal activity
levels could be detected in the range of 0.34 to 0.51 ngK1/mg total
protein/h without gender-speciﬁc differences. Samples from lymph
node showed activities of 0.97 ng K1/mg total protein/h for both
genders.
Discussion
The vitamin K cycle in liver is crucial to haemostasis. Additionally, it
also plays an essential role in extrahepatic tissues. Previous studies
demonstrated that vitamin K and the vitamin K cycle are involved in
cell growth, inﬂammation, apoptosis, and Ca2+metabolism, and are as-
sociated with diseases that include osteoporosis, cancer, diabetes and
vascular calciﬁcation [3,13]. These diverse functions are mediated by a
number of non-coagulation VKDproteins that includeMGP, osteocalcin,
Gas6, periostin, the proline-rich Gla proteins (PRGPs), as well as possi-
bly others not yet identiﬁed VKD proteins [13,32,33,23]. In addition, a
secondary vitamin K pathway is apparently involved in intracellular an-
tioxidation, for which VKORC1L1 generates vitamin K hydroquinone to
combat intracellular ROS [4].
In the present study, we focused on the role of known enzymes of
the vitamin K cycle. Therefore, we analysed mRNA transcription levels
for VKORC1, VKORC1L1, GGCX, and NQO1 in 29 different mouse tissues
(Fig. 1). We also investigated VKOR activity in all studied tissues by
use of the DTT-driven VKOR assay in order to ascertain relative contri-
butions from the VKORC1 and VKORC1L1 paralog enzymes. Limitation
of the DTT-driven VKOR assay is that VKOR activity is determined for
both VKOR enzymes. Therefore, we cannot distinguish between the ac-
tivity of the isozymes VKORC1 and VKORC1L1. There is also no speciﬁc
inhibitor available to inhibit only one of these enzymes.
As expected, highest mRNA transcription for VKORC1 and GGCXwas
found in liver, the primary organ of VKD coagulation factor synthesis
(Fig. 1A and B). Contrastingly, VKORC1L1 is transcribed in liver at only
2% relative to the level of VKORC1 (Fig. 2). This is not surprising because
VKORC1L1 is currently percieved to chieﬂy function in intracellular
redox homeostasis [4]. However, recently published data by Tie et al.
conﬁrmed the ability of VKORC1L1 to convert vitamin K 2,3-epoxide
to vitamin K quinone in vitro in a VKORC1 knock-out HEK293 cell line.
They further demonstrated that VKORC1L1-mediated VKOR activity
was sufﬁcient for γ-carboxylation of an engineered chimeric reporter
protein [12]. Accordingly, Tie et al. concluded that VKORC1L1 is likely
not a crucial enzyme for vitamin K epoxide reduction in vivo because
it can not rescue the post partum fatal bleeding phenotype of
VKORC1-/-mice under physiological conditions [5,12]. Our ﬁndings sug-
gest that VKORC1L1 cannot efﬁciently bypass VKORC1 functional deﬁ-
ciency in liver due to its low expression level (2% that of VKORC1;
Fig. 2). In addition, Hammed et al. convincingly demonstrated that
VKOR activity in liver arises chieﬂy fromVKORC1 expression by compar-
ing VKOR activity levels from wild-type and VKORC1-/- mouse micro-
somes, which is in agreement with our mRNA data [6]. However, rescue
experiments with daily vitamin K supplementation (30-50 μg/day) for
VKORC1-/- mice resulted in life-saving, but physiologically low VKD
Fig. 3. VKOR activity measurements by the DTT-driven VKOR assay in 29 different mouse tissues. This ﬁgure show mean VKOR activities (ng K1/mg total protein/h) for microsomes pre-
pared from each tissue of 5 male and 5 female mice. Tissue types are indicated below the bars. Error bars show the ranges for highest and lowest measurements representing interindi-
vidual differences between mice. The red line indicate VKOR activity of 0.5 ng K1/mg protein/h deﬁned as basal VKOR activity.
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attributed to low expression of VKORC1L1 in liver detected in our study
or, eventually to another still unknown vitamin K reductase enzyme,
requires further investigation.
Furthermore, we found transcription of NQO1, a potential vitamin K
reductase enzyme, to be low in liver - close to the detection limit.
Highest mRNA expression of NQO1was found in gastrointestinal tissue
(e.g., stomach, caecum; Fig. 1D). Several in vitro studies have shown that
NQO1 is able to reduce menadione (vitamin K3 quinone) and is far less
4-hydroxycoumarin sensitive than VKORC1. Earlier, Wallin et al. sug-
gested NQO1 might be the bypass enzyme for VKORC1 in cases of 4-
hydroxycoumarin intoxication during high-dose application of vitamin
K as an antidote [34]. However, a more recent in vitro study showed
that NQO1 does not extensively catalyse vitamin K reduction during
γ-carboxylation of VKD proteins [7]. Additionally, investigations using
HEK293T and AV12 cells, as well as a recent study using NQO1 knock-
out mice, revealed that NQO1 has no detectable function in the classical
vitamin K cycle and, thus, is not the long-thought bypass enzyme [35,Fig. 4. Gender-speciﬁc VKOR activity in glandular tissue and sex organs. Panel A: Mean VKO
(expressed in ng K1/mg total protein/h) for female (labeled as "f") and male (labeled as "m").
bars represent the SEM for each measurement (pooled samples of 5 male or 5 female mice).11]. As NQO1 transcription in liver is only low-level, our results provide
further evidence that NQO1 does not contribute to the classical vitamin
K cycle and, subsequently, to γ-carboxylation of VKD proteins. Also, in
all other tissues investigated there is no positive correlation between
the mRNA transcription levels of VKORC1, GGCX and NQO1.
Besides the high transcription levels of VKORC1 and GGCX in liver,
mRNA quantiﬁcation revealed ubiquitous expression of VKORC1 and
GGCX in all 29 tissues investigated. Most interestingly, a high expression
and VKOR activity in extrahepatic secretory tissues like salivary gland,
lung, prostate, and mammary gland (for female mice) were found
(Figs. 1A,B, and 4A).
It was reported that the VKD protein MGP is highly expressed in
adult lung. MGP is known to act as calciﬁcation inhibitor and might be
a candidate for this function in lung also [36]. MGP-/- mice die about
eight weeks after birth due to aortic rupture. By that time, all elastic ﬁ-
bers in the vascular media of medium and large arterial vessels are
completely calciﬁed [36]. It was also reported that patients treated
with 4-hydroxycoumarin oral anticoagulants, which directly inhibitR activity values for microsomes for salivary gland, mammary gland and adrenal gland
Panel B: Mean VKOR activity for microsomes for uterus, ovary, testis and prostate. Error
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[37]. Therefore, MGP might be needed to protect the lung vessels
against calciﬁcation - especially in the alveoli, where oxygen and carbon
dioxide exchange takes place [36,38]. In addition, MGP is believed to be
a key protein involved in the manifestation of warfarin embryopathy.
Interestingly, MGP is not expressed during early lung development
[36]. This absence of MGP expression possibly explains why no patho-
logical lung phenotypes are observed in cases of warfarin embryopathy.
Warfarin embryopathy is induced by warfarin administration during
pregnancy and is asscociated with hypoplasia of the nasal bridge, stip-
pled epiphyses and bone growth retardation. In this chondrodysplasia
punctata-like phenotype, hyaline cartilage is hypercalciﬁed especially
in joints, larynx, and trachea. Hyaline cartilage of the epiphyses seems
to be also affected in VKORC1-/- mice, which are born with shorter
bones [5]. Additionally, in MGP-/- mice, vascular smooth muscle cells
(VSMCs) differentiate to bone-like cells. Thus, other types of smooth
muscle cells might also be affected by deﬁciency of the classical vitamin
K cycle. Smoothmuscle cells are not only found inwalls of blood vessels
or bronchioles of lung, but are also found in lymphatic vessels, urinary
bladder, uterus, male and female reproductive tract, gastrointestinal
tract, and respiratory tract. Therefore, MGPmay have a protective func-
tion in other types of smooth muscle and might explain the additional
high transcription of VKORC1 and GGCX in prostate and mammary
gland. Vena cava and aorta, which contain VSMCs, show fairly high ex-
pression of VKORC1 and GGCX, consistent with MGP being protective
against calciﬁcation.
The high transcription levels of VKORC1 and GGCXwe have detected
in exocrine tissues including salivary gland, prostate, lung andmamma-
ry gland may be correlated and, thus, may point to roles for as yet un-
known VKD proteins in exocrine tissues.
Addressing the function of VKORC1L1, Westhofen et al. ﬁrst demon-
strated the involvement of this enzyme in vitamin K-dependent intracel-
lular antioxidation and proposed VKORC1L1 may be responsible for the
transfer of reducing equivalents to ER membrane-associated antioxida-
tive pathways [4]. In concordancewith this hypothesis of universal cellu-
lar ROS protection, our data show a uniform basal expression of
VKORC1L1 in all tissues investigated (Fig. 1C). However, highest transcrip-
tion of VKORC1L1was found in brain at 2.5-fold higher mean levels com-
pared to salivary gland, the tissue with the next-highest VKORC1L1
transcription level. Brain generates greater levels of free radicals than
any other organ and is particulary susceptible to oxidative stress [39].
Therefore, oxidative cell-damaging free radicals and free radical-
generating processesmust be neutralized by antioxidative defencemech-
anisms. [40] Due to the substantial requirement for antioxidative activity
in brain,wehypothesize that high transcription levels ofVKORC1L1might
be related to ROS scavenging and oxidative protection in brain (Fig. 1C).
In conclusion, our data demonstrate ubiquitous mRNA transcription
for VKORC1, VKORC1L1 and GGCX, as well as ubiquitous VKOR activity,
for all tissues examined, suggesting an important role of the vitamin K
cycle in extrahepatic as well as in hepatic tisues. A quantitative compar-
ison regarding differential transcription levels revealed liver as the tis-
sue of highest VKORC1 and GGCX expression, and brain as the tissue of
highest VKORC1L1 expression. The very low transcription level of
VKORC1L1 in liver supports the exclusion of VKORC1L1 as a bypass en-
zyme for VKORC1. Furthermore, low transcription levels of NQO1 in
liver indicates that NQO1 has no function in the classical vitamin K
cycle with respect to VKD coagulation proteins. High VKORC1 and
GGCX transcription levels toghether with VKOR activity levels in exo-
crine tissues including lung, female mammary glands, salivary gland,
prostate and pancreas point to a substantial role of the classical vitamin
K cycle in these tissues. γ-carboxylation of VKD proteins such as MGP
appears to be essential for homeostasis of hyaline cartilage as well as
of several types of smooth muscle cells. Further investigation is neces-
sary to characterize the role of VKOR activity in extrahepatic tissues, to
elucidate speciﬁc functions of VKD proteins and to identify new VKD
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